CLEVELAND, Nov. 14, 2011 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX), a leader in the emerging field of regenerative medicine, today announced its financial results for the third quarter of 2011. The Company also announced earlier today that it had successfully regained the exclusive rights to MultiStem® for the cardiovascular field through the mutual termination of its collaboration with Angiotech Pharmaceuticals, Inc. (Angiotech), allowing it greater flexibility in clinical development and the opportunity to pursue new business collaborations within or including this important field.
